The case for value-based reinsurance in Asia
Why traditional reinsurance can no longer bend the medical cost curve — and how capitation with primary-care providers changes the maths.
WellDoc Reinsurance Company Limited is a newly approved Hong Kong reinsurer built for one purpose: enabling every health insurer to underwrite medical risk sustainably, as our population ages and medical costs climb.
WellDoc Re exists to keep quality health protection within reach of every generation.
To make Hong Kong the leading medical reinsurance hub in Asia.
We enable every health insurer to underwrite medical risk sustainably.
A company's name sets the tone for everything it does.
Doc declares where WellDoc Re stands: anchored on clinicians and on evidence-based practice.
Look closely at the W in our logo.
They stand for the three things health protection must be:
The third A is drawn in gold — and it is deliberately broken.
WellDoc Re is the reinsurance arm of The Healthcare Group.
Our promoter and sponsor — The Healthcare Group.
In 2021, the Group became an independently managed entity.
WellDoc Re is the payment-and-insurance arm of that ecosystem.
via WellDoc Reinsurance Holdings Ltd
One ecosystem, two arms.
Founded in Hong Kong by family doctors and insurance professionals.
The in-house GP training programme begins.
The first public-private GOLDTM clinic opens in Guangzhou.
Enabling seamless online and offline care.
UMP China becomes The Healthcare Group.
Health Centres open inside public Tier 3 hospitals.
Pioneering integrated GBA outpatient insurance products.
The reinsurance arm is approved.
Traditional reinsurance controls medical cost downstream. WellDoc Re works upstream.
Through capitation, we share risk with GPs.
Continuous, real-time clinical data.
A doctor-led primary-care system.
Built for one corridor and one model.
A reinsurer that thought only about insurers could never solve this problem.
Today's healthcare system pulls three groups against one another.
WellDoc Re realigns all three around a single shared goal.
Sustainable underwriting and capital efficiency.
Affordability and continuity.
Doctor-led, preventive care.
A partner in structural reform.
Appropriate, well-triaged demand.
Sustainable primary-care economics.
A model that values prevention.
A channel for value, not volume.
Built in partnership with the public health system.
WellDoc Re does not vertically own its providers.
Five stages, and the last feeds back into the first.
The best-managed claim is the one that never happens.
A prospective payment tied to outcomes.
Unparalleled visibility into the real cost of care.
Cost control engineered in at the design stage.
Continuous data drives forward-looking pricing.
The flywheel: every cycle sharpens the next.
Data triggers a clinical response before the claim.
More cedants mean sharper pricing for everyone.
What aligns the doctor with the patient.
Through the Group, our founders pioneered VBC here.
VBC asks: how well is the patient?
Fewer avoidable hospital admissions, documented savings.
WellDoc Re builds in the design choices of the world's most innovative VBC organisations.
We address both of the insurer's rational concerns directly.
We offer to co-build a better-performing book.
WellDoc Re acts on the cost itself.
Incentives are aligned three ways, not extracted one way.
Transparency is the trust mechanism.
From conventional treaties to value-based structures.
A defined menu a direct insurer can build a partnership around.
Write value-based products at scale.
Clinical and actuarial support.
A direct loss-ratio lever.
Optimising against HKRBC and IFRS 17.
A rated network across HK and the GBA.
Ready-to-deploy clinical programmes.
Lower-cost treatment options.
The clinical core of every product.
The insurer owns the brand.
Forward-looking pricing from clinical data.
The engine of cost-steered design.
They compound as more insurers join.
Rapid deployment, no legacy drag.
Support for cedants navigating reserving, IFRS 17 and IA engagement.
Deep insurance expertise paired with genuine clinical and VBC credentials.

Chairs the Board and oversees strategy and governance.

Over 20 years of management experience in listed healthcare groups.

Co-CEO of The Healthcare Group.

Over 50 years in general and life insurance.

Founder of the GOLDTM training programme.

18+ years across health insurance and reinsurance.

Former Secretary for Financial Services and the Treasury.

Former CEO of HSBC Insurance (Asia-Pacific) and BOC Life.

Senior, independent perspective on governance and risk.

Leads provider management and network performance.

Judith has a distinctive blend of nursing leadership and insurer-facing claims experience — including medical claims assessment at Cigna. She leads our clinical claims review and provider partnership effort.

Leads technology deployment and systems integration.

Leads enterprise risk management and HKRBC compliance.

20+ years in Hong Kong health insurance.

Formerly Partner at Linklaters.
Board and management appointments remain subject to regulatory approval.
A growing library of WellDoc Re's perspectives on medical reinsurance, value-based care and the future of health protection across Hong Kong and the Greater Bay Area.
Why traditional reinsurance can no longer bend the medical cost curve — and how capitation with primary-care providers changes the maths.
A view on the 2039 demographic shift and what insurers must do today to keep premiums affordable through renewal.
Lessons from a decade of GP-led primary care in the GBA, and what they imply for insurer product design.
Announcement of the formation of Hong Kong's value-based health reinsurer, promoted by The Healthcare Group.
Conversations with our Co-CEOs and Chief Medical Officer on building a reinsurer for the GBA era.
A curated selection of Hong Kong and regional press coverage of WellDoc Re and the value-based care movement.
An annual benchmark of inpatient, oncology and chronic-care pricing across Hong Kong and Greater Bay Area providers.
Quantifying the avoidable-admission impact of structured primary-care management for diabetes and hypertension.
Where Hong Kong policyholders are choosing GBA providers, and what it means for insurer product strategy.
New publications will be added as they are released. To request early access or to subscribe to our distribution list, please get in touch.
Each study foregrounds the insurer's branded product.
A leading Hong Kong insurer launches a mid-tier medical plan.
An insurer adds a diabetes or hypertension management benefit.
Each study will carry verified outcome data once a partner product is live.
WellDoc Re works through every health insurer, on an open-architecture basis.
Start a conversation →